Skip to main content
Premium Trial:

Request an Annual Quote

Hyris Gets CE-IVD Mark for SARS-CoV-2 Cellular Immunity Test

NEW YORK — Hyris said on Friday that it has received CE-IVD marking for its T-Cell Test for tracking and monitoring T-cell immunity to SARS-CoV-2.

The qPCR-based test, which was developed by Mount Sinai researchers and exclusively licensed by London-based Hyris, quantifies the messenger RNA of CXCL10, a chemokine that linearly correlates with the activation of T cells, in whole blood. When a patient is exposed to SARS-CoV-2 antigens, the T cells release interferon gamma, which stimulates monocytes in the blood to produce CXCL10. Measuring the expression of CXCL10 can then be used to quantify immunity.

"Long-term protection from viral infections is mediated by both the humoral … and cellular … immune pathways," Lorenzo Colombo, general manager and chief technology officer at Hyris, said in a statement. "While SARS-CoV-2-specific IgG and neutralizing antibody quantification are being used as the typical clinical endpoints to determine immune protection, a precise measurement of cellular responses underlying virus protection also represents an important parameter of immune defense."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.